Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03874325 · ClinicalTrials.gov registry record · Phase 2
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT03874325 is a Phase 2 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 17 participants.
The verdict
NCT03874325, a Phase 2 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study is to find out if an investigational drug called Durvalumab (MEDI4736) given together with a standard of care aromatase inhibitor drug can help people with breast cancer.
Interventions
- DRUG Letrozole 2.5mg
- DRUG Durvalumab
- DRUG Anastrozole 1mg
- DRUG Exemestane 25 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-04-26 |
| Est. Completion | 2021-01-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03874325
The ClinicalTrials.gov registry entry for NCT03874325 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Letrozole 2.5mg is the first listed.
NCT03874325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03874325 about?
NCT03874325 is a clinical study titled "Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer". This study is to find out if an investigational drug called Durvalumab (MEDI4736) given together with a standard of care aromatase inhibitor drug can help people with breast cancer.
What is the current status of trial NCT03874325?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2019-04-26. Estimated completion is 2021-01-06.
What interventions are being tested in trial NCT03874325?
The interventions under investigation include: Letrozole 2.5mg (DRUG), Durvalumab (DRUG), Anastrozole 1mg (DRUG), Exemestane 25 MG (DRUG).
Who is sponsoring clinical trial NCT03874325?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.